We have a limited supply of COVID-19 vaccines and are offering them to eligible patients based on state and federal guidelines. Please do not call us for a vaccine appointment. We are notifying patients individually when they can schedule. so we can notify you. Learn more about the .
Clinical Trials and Research Studies
An open-label phase I multi-center study to determine the recommended dose of the chimeric antigen receptor T-cell treatment CYAD-211 after a non-myeloablative preconditioning chemotherapy in multiple myeloma patients with relapsed or refractory diseaseLearn More
A MULTI-CENTER OPEN LABEL PHASE 1/2 STUDY OF CYT-0851 AN ORAL RAD51 INHIBITOR IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES AND ADVANCED SOLID TUMORSLearn More
A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell TransplantLearn More
Phase 2 Trial of Intensive Chemo-immunotherapy with Carfilzomib Lenalidomide Dexamethasone and Daratumumab for Relapsed/Refractory Myeloma in the context of salvage autologous hematopoietic cell transplantation.Learn More